Eisai INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$36Mgeneral payments (2019-2025)
$52Kresearch payments (2019-2025)
68,725clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $6.1M
2020 $4.3M
2021 $4.8M
2022 $4.4M
2023 $4.7M
2024 $6.7M
2025 $5.0M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Neurology (Psychiatry & Neurology) $9.0M
Hematology & Oncology $4.1M
Medical Oncology $3.8M
Gynecologic Oncology $2.5M
Psychiatry $2.4M
Neurology With Special Qualifications In Child Neurology $2.3M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Douglas Nordli Chicago, IL Neurology With Special Qualifications In Child Neurology $598,740.00
Daniel Weintraub Philadelphia, PA Psychiatry $455,578.91
Mahdi Taha Boca Raton, FL Medical Oncology $410,077.63
Amina Ahmed Chicago, IL Gynecologic Oncology $394,697.56
Ghassan Abou-Alfa New York, NY Medical Oncology $366,896.87
Arnab Basu Jacksonville, FL Hematology & Oncology $350,803.17
John Hemphill Savannah, GA Neurology With Special Qualifications In Child Neurology $312,697.17
Michael Morse Durham, NC Hematology & Oncology $287,249.54
Heidi Godoy Albany, NY Gynecologic Oncology $277,346.53
Pierre Gholam Cleveland, OH Gastroenterology (Internal Medicine) $265,133.58

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.